Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lupin launches Fidia's Hyalgan in India

This article was originally published in Scrip

Executive Summary

Lupin has launched a sodium hyaluronate injection product, Hyalgan, on the Indian market for the treatment of osteoarthritis, under a licensing arrangement with Fidia. Lupin told Scrip that it has exclusive local rights to the product and would pay royalties to the Italian company, adding that the product had been test marketed over the past six months across the country. Hyalgan is believed to be priced at a discount to Genzyme's single-injection Synvisc-One (hylan G-F 20). Hyalgan is recommended for patients with stage one to three osteoarthritis to relieve the acute pain associated with the disorder. The Indian osteoarthritis market is currently valued at about Rs1.50 billion ($32.9 million), with a patient base of more than 15 million. By 2011, India is projected to have 66 million people (aged more than 65 years) in the high-risk segment for osteoarthritis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts